Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03627299 · ClinicalTrials.gov registry record · Phase 4
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03627299: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT03627299 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03627299, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 4 weeks post-renal transplant.
Interventions
- DRUG 300mg glecaprevir/pibrentasivir 120mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2021-09-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03627299
The ClinicalTrials.gov registry entry for NCT03627299 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 300mg glecaprevir/pibrentasivir 120mg is the first listed.
NCT03627299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03627299 about?
NCT03627299 is a clinical study titled "Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors". In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) admini...
What is the current status of trial NCT03627299?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-09-25. Estimated completion is 2021-09-20.
What interventions are being tested in trial NCT03627299?
The interventions under investigation include: 300mg glecaprevir/pibrentasivir 120mg (DRUG).
Who is sponsoring clinical trial NCT03627299?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.